These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33045338)

  • 21. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant
    Li J; Fu Y; Zhang J; Zhao Y; Fan X; Yu L; Wang Y; Zhang X; Li C
    J Chemother; 2020 Nov; 32(7):359-367. PubMed ID: 32427074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.
    Liang W; Liu XF; Huang J; Zhu DM; Li J; Zhang J
    BMC Infect Dis; 2011 Apr; 11():109. PubMed ID: 21521536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
    Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
    Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
    [No Abstract]   [Full Text] [Related]  

  • 25. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
    Ju YG; Lee HJ; Yim HS; Lee MG; Sohn JW; Yoon YK
    Sci Rep; 2022 May; 12(1):7541. PubMed ID: 35534512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
    Yang YS; Lee Y; Tseng KC; Huang WC; Chuang MF; Kuo SC; Lauderdale TL; Chen TL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4047-54. PubMed ID: 27114274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant
    Yu L; Zhang J; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Li C; Zhang X
    Front Cell Infect Microbiol; 2019; 9():422. PubMed ID: 31921701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Various antibiotic combinations against carbapenem resistant Acinetobacter baumannii infections and in vitro synergy test results (2002-2016)].
    Zarakolu P; Ayaz ÇM; Metan G
    Mikrobiyol Bul; 2018 Apr; 52(2):190-197. PubMed ID: 29933736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Singkham-In U; Chatsuwan T
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):169-174. PubMed ID: 29433997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Müderris T; Dursun Manyaslı G; Sezak N; Kaya S; Demirdal T; Gül Yurtsever S
    Eur J Med Res; 2024 Jun; 29(1):331. PubMed ID: 38880888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
    Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
    Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
    Deveci A; Coban AY; Acicbe O; Tanyel E; Yaman G; Durupinar B
    J Chemother; 2012 Oct; 24(5):247-52. PubMed ID: 23182043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
    Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
    Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model.
    Liu X; Zhao M; Chen Y; Bian X; Li Y; Shi J; Zhang J
    Int J Antimicrob Agents; 2016 Nov; 48(5):559-563. PubMed ID: 27670371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).
    Seifert H; Blondeau J; Lucaßen K; Utt EA
    J Glob Antimicrob Resist; 2022 Dec; 31():82-89. PubMed ID: 35948242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.